BAG6 and non-small cell lung carcinoma: Briefly, the following improvements have been proposed: (1) Based on the phase II trial data on NSCLC [81], DCexo immunotherapy was likely most effective in patients with measurable levels of serum BAG6, which is possibly related to NKp30 functional defects.